Scadenza: 30 November 2021
Topic:
The Fight Kids Cancer programme aims to deliver innovative and relevant research for paediatric cancer, as well as to strengthen the development of pan-European research initiatives. An ambition is to foster closer working ties between basic translational and clinical researchers. Specifically, this should encourage collaboration among the leading academic laboratories and practitioners, and lead to novel innovative
projects. It has four main objectives:
1. To realise real impact on young patients: Improve their survival rate and reduce toxicity to
restore young patients to full health after treatment
2. To advance cutting-edge science to further the knowledge of paediatric malignancies.
3. To support improved interdisciplinary research, methods and collaborations for tackling the
issues of today.
4. To strengthen collaboration and the development of scientific capacity across Europe.
Projects are expected to propose research on either Early phase clinical trials or Translational research. Applicants to both categories are encouraged to address innovative interventions or approaches towards novel treatment (such as innovative drugs, artificial intelligence, imaging, radiotherapy, surgical approaches…)
The two categories of projects are:
1. Early Phase Clinical Trials to evaluate innovative therapies for children and adolescents with cancer The key elements of the proposals are:
Documentation for provision of investigational drug(s) must be provided
Demonstration that the trial is conducted and financed in at least 2 European countries
Designs of early phase clinical trials which will rapidly and efficiently assess the innovative agents are strongly encouraged
Co-funding of clinical trials is possible, however precise details, justification and timeline must be provided
Enrolment of patients must commence not later than 12 months from the start of funding
Immune oncology approaches are welcome
Study of the impact on the quality of life of the studied treatment regimen is strongly encouraged
Platform trials are welcome.
2. Translational research projects addressing childhood and adolescent cancers. Proposals are encouraged on:
Projects identifying novel targets of action
Projects that may result in innovative new therapies or better models of disease.
Projects that are ancillary to ongoing/completed clinical trial
Pre-clinical projects including high-risk / high return proposals,
Projects that leverage paediatric tumour models, will be considered.
Multi-disciplinary or multi-institution collaborations are strongly encouraged.
A clear pathway to a clinical trial should be included
Ente finanziatore:
European Science Foundation
Budget complessivo:
up to 4 million euros
Duration of the project: the duration will be 2 years for translational projects and 3 years for clinical trial projects.
Who can participate:
Funding is aimed at supporting new research projects across Europe. The lead institution must be from the list of eligible countries, with preference given to institutions with a strong track record in paediatric cancer research. Other project partners are encouraged and can be from related fields of expertise, providing they operate as not-for-profit.
Status:
Closed
Quota finanziabile:
clinical trials with a maximum of 1,5 million per project
translational projects (with a maximum of 500 000 euros per project.
Topic:
The Fight Kids Cancer programme aims to deliver innovative and relevant research for paediatric cancer, as well as to strengthen the development of pan-European research initiatives. An ambition is to foster closer working ties between basic translational and clinical researchers. Specifically, this should encourage collaboration among the leading academic laboratories and practitioners, and lead to novel innovative
projects. It has four main objectives:
1. To realise real impact on young patients: Improve their survival rate and reduce toxicity to
restore young patients to full health after treatment
2. To advance cutting-edge science to further the knowledge of paediatric malignancies.
3. To support improved interdisciplinary research, methods and collaborations for tackling the
issues of today.
4. To strengthen collaboration and the development of scientific capacity across Europe.
Projects are expected to propose research on either Early phase clinical trials or Translational research. Applicants to both categories are encouraged to address innovative interventions or approaches towards novel treatment (such as innovative drugs, artificial intelligence, imaging, radiotherapy, surgical approaches…)
The two categories of projects are:
1. Early Phase Clinical Trials to evaluate innovative therapies for children and adolescents with cancer The key elements of the proposals are:
Documentation for provision of investigational drug(s) must be provided
Demonstration that the trial is conducted and financed in at least 2 European countries
Designs of early phase clinical trials which will rapidly and efficiently assess the innovative agents are strongly encouraged
Co-funding of clinical trials is possible, however precise details, justification and timeline must be provided
Enrolment of patients must commence not later than 12 months from the start of funding
Immune oncology approaches are welcome
Study of the impact on the quality of life of the studied treatment regimen is strongly encouraged
Platform trials are welcome.
2. Translational research projects addressing childhood and adolescent cancers. Proposals are encouraged on:
Projects identifying novel targets of action
Projects that may result in innovative new therapies or better models of disease.
Projects that are ancillary to ongoing/completed clinical trial
Pre-clinical projects including high-risk / high return proposals,
Projects that leverage paediatric tumour models, will be considered.
Multi-disciplinary or multi-institution collaborations are strongly encouraged.
A clear pathway to a clinical trial should be included
Who can participate:
Funding is aimed at supporting new research projects across Europe. The lead institution must be from the list of eligible countries, with preference given to institutions with a strong track record in paediatric cancer research. Other project partners are encouraged and can be from related fields of expertise, providing they operate as not-for-profit.
Programme:
Consortium:
Status: Open
Total budget:
up to 4 million euros
Funding rate:
clinical trials with a maximum of 1,5 million per project
translational projects (with a maximum of 500 000 euros per project.
